Go to virtual 3D site

Overview


In accordance with current government guidelines on the COVID-19 pandemic, the third CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held on 23rd and 24th March 2021 as a virtual event. Genome Engineering, including zinc-finger nucleases, TALENs and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline. This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus. The scientific program for this CRISPR in Drug Discovery meeting will include:

Large-scale CRISPR functional genomics studies for drug target identification and validation Application of genome engineering in developing biological models of disease from single cells through to complex in vitro tissue systems and in vivo models Cutting edge CRISPR genome engineering technologies and their emerging applications A perspective from technology leaders toward the future therapeutic applications of genome engineering We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech and CRO's online to hear talks given by speakers at the cutting edge of genome engineering, network at the virtual exhibition and gain strategic insights into solutions for increasing the success of drug discovery and development.



Venue: Web Event
Organiser Contact Details:
ELRIG UK

T: 07484 113971
info@elrig.org

CRISPR in Drug Discovery 2021
Bassett
Dr Andrew Bassett
Head of Research (Cellular Operations)
Wellcome Sanger Institute
Speaker
Bryant
Dr Christopher Bryant
Postdoctoral Fellow
Wellcome Sanger Institute
Speaker
Buerckstuemmer
Dr Tilmann Buerckstuemmer
CSO
Aelian Biotechnology
Speaker
Exhibitor
Carusillo
Antonio Carusillo
PhD Student
Center for Transfusion Medicine and Gene Therapy
Delegate
Speaker
Cooper
Dr Sarah Cooper
Senior Staff Scientist
Wellcome Sanger Institute
Speaker
Corn
Prof Jacob Corn
Principal Investigator
ETH Zürich
Speaker
Datlinger
Dr Paul Datlinger
Post Doc
CeMM Research Center for Molecular Medicine, Vienna
Speaker
Davis
Dr Richard Davis
Assistant Professor
Leiden University Medical Center
Speaker
Dhaliwal
Kam Dhaliwal
SVP Alliance Management
bit.bio
Speaker
Exhibitor
Elling
Ulrich Elling
Principal Investigator
Institute of Molecular Biotechnology, IMBA, Vienna
Speaker
Garnett
Mathew Garnett
Senior Group Leader
Wellcome Sanger Institute
Speaker
Gechtman
Zeev Gechtman
Technical Product Manager
Abcam
Speaker
Exhibitor
Goncalves
Manuel Goncalves
LUMC
Speaker
Hague
Stephen Hague
Science and Technology Advisor
10x Genomics
Speaker
Komor
Prof Alexis Komor
Assistant Professor
UCSD
Speaker
Lancaster
Dr Madeline Lancaster
MRC Investigator
MRC Laboratory of Molecular Biology, Cambridge
Speaker
le Sage
Dr Carlos le Sage
Manager
Horizon Discovery Ltd
Speaker
Mali
Prashant Mali
UCSD
Speaker
Maratou
Dr Klio Maratou
GSK Fellow and Scientific Leader
GlaxoSmithKline
Speaker
Maresca
Dr Marcello Maresca
Senior Principal Scientist/Director
AstraZeneca
Speaker
Mattis
Dr Katia Mattis
Research Scientist
IotaSciences
Speaker
Mussolino
Dr Claudio Mussolino
Group Leader
University of Freiburg
Speaker
Ramos
Mr Pedro Ramos
ESR; PhD student
i3S - IBMC; ICBAS
Speaker
Sienski
Dr Greg Sienski
AstraZeneca
Speaker
Steinmetz
Dr Lars Steinmetz
PI & Senior Scientist
EMBL
Speaker
Tasca
Francesca Tasca
PhD student
LUMC
Delegate
Speaker
Ward
Michael Ward
NIH/NINDS
Speaker
Wilkens
Dr Kai Wilkens
Head of Europe
Synthego
Speaker

Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021